Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 26, 2023 Category: Gastroenterology Authors: The Polaris Observatory Collaborators Tags: Research Article Source Type: research
The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories
This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 26, 2023 Category: Gastroenterology Authors: The Polaris Observatory Collaborators Tags: Research Article Source Type: research
A rare cause of painful hepatomegaly
A 50-year-old female was admitted to our inpatient service due to abdominal pain, nausea, and progressive fatigue. The symptoms started a few weeks before hospitalization when she was treated with oral antibiotics for a dental infection. Vitals were normal. Physical examination showed an enlarged liver and bilateral leg edema. Medical history included smoldering myeloma (diagnosed a few weeks before admission), autoimmune thyroiditis (since 2018), and Sjogren ’s syndrome (since 2020). Labs demonstrated leukocytosis (15x109/L, with an upper limit of normal [ULN] of 11x109/L), normocytic anemia (hemoglobin 11 g/dl), normal...
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Authors: Alberto Zanetto, Marco Senzolo, Filippo Pelizzaro, Claudia Mescoli, Stefania Rizzo Tags: What Is Your Diagnosis? Source Type: research
From the Editor ’s Desk...
The terms NAFLD and NASH are limited by their reliance on exclusionary confounder terms and potentially stigmatising language. Therefore, to overcome these limitations, three pan-national liver associations Rinella et al. led a modified Delphi process to generate consensus on alternative nomenclature and criteria for fatty/steatotic liver diseases. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research
Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
Looking for exciting research to be presented at EASL Congress 2024! Submit your abstract by 16 January.
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
Register with early fees for the EASL Liver Cancer Summit!
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
Let ’s unite Hepatology! Become an EASL member today and discover your benefits
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
EASL is supporting six major EU-funded projects on the liver. Discover them!
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
JHEP at a glance (December 2023)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Source Type: research
Using NIS2+ ™ to identify at-risk MASH in clinical trials
Jimmy Lai has served as a speaker and advisory board member for Gilead Sciences. Vincent Wong has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna; and a speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk, and Unilab. He has received a research grant from Gilead Sciences, and is a co-founder of Illuminatio Medical Technology Limited. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 25, 2023 Category: Gastroenterology Authors: Jimmy Che-To Lai, Vincent Wai-Sun Wong Tags: Editorial Source Type: research
Detour of bile acid routes as therapeutic roadmap for cholemic nephropathy
Acute kidney injury (AKI) is frequent in hospitalized patients with chronic liver disease (i.e. up to 50% in some studies) and is associated with high morbidity and mortality.1 –3 Causes of AKI in patients with liver disease are numerous and differential diagnosis remains a clinical conundrum in 2023.4,5 This is based on (i) the frequently observed overlap of several initiating factors and diseases and (ii) the lack of non-invasive clinical tests showing high sensitivity and specificity to discriminate different entities of AKI in patients with liver disease. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 24, 2023 Category: Gastroenterology Authors: Peter Fickert Tags: Editorial Source Type: research
Detour of bile acids routes as therapeutic roadmap for cholemic nephropathy
Acute kidney injury (AKI) is frequent in hospitalized patients with chronic liver disease (i.e. up to 50% in some studies) and associated with high morbidity and mortality 1,2,3. Causes of AKI in liver patients are numerous and differential diagnosis remains a clinical conundrum in 2023 4,5. This is founded in (i) the frequently observed overlap of several initiating factors and diseases and (ii) the lack of non-invasive clinical tests showing high sensitivity and specificity to discriminate different entities of AKI in liver patients 4,5. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 24, 2023 Category: Gastroenterology Authors: Peter Fickert Tags: Editorial Source Type: research
E. coli´s fight against TYROnny: Designing a bacterial strain to tackle tyrosinemia type 1
Tyrosinemia type 1 (HT-1) is a rare autosomal recessive disease caused by a deficiency of fumarylacetoacetate hydrolase (FAH)1,2 and occurs in approximately 1 in 100,000 newborns.3 The lack of FAH leads to an increase in intermediary products of the degradation of phenylalanine and tyrosine to fumarate and acetoacetate2 (Fig. 1A). Next to the name-giving increase of tyrosine levels in the sera of patients suffering from this disease, an elevation of fumarylacetoacetate (FAA), the direct substrate of FAH, can be detected2 (Fig. 1B). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 23, 2023 Category: Gastroenterology Authors: J öran Lücke, Samuel Huber Tags: Editorial Source Type: research
